Time to initiation of treatment with polymyxin B cartridge hemoperfusion in septic shock patients

Blood Purification

Volumn 33, Issue 4, 2012, Pages 252-256

  Takeyama, Naoshi ^a   Noguchi, Hiroshi ^a   Hirakawa, Akihiko ^a   Kano, Hideki ^a   Morino, Kazuma ^b   Obata, Toru ^c   Sakamoto, Tetsuya ^d   Tamai, Fumihiro ^e   Ishikura, Hiroyasu ^f   Kase, Youichi ^g   Kobayashi, Makoto ^h   Naka, Toshio ⁱ   Takahashi, Yoshiki ^j  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b Life style Related Diseases   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Oita Sanai Medical Center   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Tajima Emergency and Critical Care Medical Center   (Japan)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j SHOWA UNIVERSITY   (Japan)

more..

Author keywords

Catecholamine; Hemoperfusion; Multicenter cohort study; Polymyxin B; Pulmonary oxygenation; Septic shock; Sequential Organ Failure Assessment score; Timing of initiation

Indexed keywords

CATECHOLAMINE; POLYMYXIN B;

AGED; ARTICLE; ARTIFICIAL VENTILATION; DRUG EFFICACY; FEMALE; HEMOPERFUSION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OXYGENATION; PERFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK;

AGED; ANTI-BACTERIAL AGENTS; CATECHOLAMINES; COHORT STUDIES; FEMALE; HEMOPERFUSION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; POLYMYXIN B; PROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL ANALYSIS; VENTILATORS, MECHANICAL;

EID: 84859137851     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000336341     Document Type: Article

References (23)

1. Rietschel ET, Brade H, Holst O, Holst O, Brade L, Muller-Loennies S, Mamat U, Zahringer U, Beckmann F, Seydel U, Brandenburg K, Ulmer AJ, Mattern T, Heine H, Schletter J, Loppnow H, Schonbeck U, Flad HD, Hauschildt S, Schade UF, Di Padova F, Kusumoto S, Schumann RR: Bacterial endotoxin: chemical constitution, biological recognition, host response and immunological detoxification. Curr Top Microbiol Immunol 1996; 216: 39-81.
2. Cruz DN, Bellomo R, Ronco C: Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 444-451.
3. Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin absorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-114.
4. Racholin JS, Foster D, Dellinger RP: Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 111-118.
5. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
6. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1982; 101: 1644-1655.
7. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-710.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
9. Cohen J: The detection and interpretation of endotoxemia. Intensive Care Med 2000; 26:S51-S56.
10. Tsushima K, Kubo K, Yoshikawa S, Koizumi T, Yasuo M, Furuya S, Hora K: Effects of PMX-DHP treatment for patients with directly induced acute respiratory distress syndrome. Ther Apher Dial 2007; 11: 138-145.
11. Ikeda T, Ikeda K, Nagura M, Taniuchi H, Matsushita M, Kiuchi S, Kuroki Y, Suzuki K, Matsuno N: Clinical evaluation of PMXDHP for hypercytokinemia caused by septic multiple organ failure. Ther Apher Dial 2004; 8: 293-298.
12. Shimizu T, Hanasawa K, Sato K, Umeki M, Koga N, Naganuma T, Sato S, Shimonishi T, Ikeda T, Matsuno N, Ono S, Saitoh H, Satoh K, Otani Y, Endo Y, Eguchi Y, Tani T, PMX Treatment Study Group: Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch Surg 2009; 394: 303-311.
13. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri J, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
14. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11:R47.
15. Zagli G, Bonizzoli M, Spina R, Cianchi G, Pasquini A, Anichini V, Matano S, Tarantini F, Di Filippo A, Maggi E, Peris A: Effects of hemoperfusion with an immobilized polymyxin-B fiber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anesthesiol 2010; 76: 1-8.
16. Berto P, Ronco C, Cruz D, Melotti RM, Antonelli M: Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Blood Purif 2011; 32: 331-340.
17. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-405.
18. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
19. Hussein MH, Kato T, Sugiura T, Daoud GA, Suzuki S, Fukuda S, Sobajima H, Kato I, Togari H: Effect of hemoperfusion using polymyxin B-immobilized fiber on IL-6, HMGB-1, and IFN, in a neonatal sepsis model. Pediatr Res 2005; 58: 309-314.
20. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, Inoue S, Nakagawa T, Noguchi H: Apheresis of activated leukocytes with an immobilized polymyxin B fiber in patients with septic shock. Shock 2010; 34: 461-466.
21. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I: Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 2000; 470: 151-155.
22. Abe S, Hayashi H, Seo Y, Matsuda K, Kamio K, Saito Y, Usuki J, Azuma A, Kudo S, Gemma A: Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif 2011; 32: 310-316.
23. Varga K, Wagner JA, Bridgen DT, Kunos G: Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-1044.